April 24, 2026 5:17pm

Afraid of the up-coming geo-political and macro events as retail investors “call the ball”

Hope for a restart of negotiations is not a technical influence

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

TGIF, yard work is the treat i.e. labor this weekend

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions.  I am more frequently right than consequentially wrong; thus, mostly EARLY in my prognostications!

Thursday’s RMi Closing Bell: Uncertainty, oil pricing, unexpected higher jobless claims’ push sector’s retreat … https://www.regmedinvestors.com/articles/14393

Friday’s RMi Pre-opening: Stand fast … https://www.regmedinvestors.com/articles/14394

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

What happened and some of the whys with the numbers behind

… it’s NOT always about BUYs/SELLs … it’s about knowing when and what!

 

Friday: The Dow closed DOWN -79.61 points or -0.16%, the S&P closed UP +56.68 points or +0.80% while the Nasdaq closed UP +398.094 points or +1.63%

  • Theme of the session: betting on Iran to re-ignite peace talks

Friday (my) 40-company covered sector’s advance/decline line opened negative with 1 incliner, 36 decliners and 3 flats, ending with a negative close of 11 incliners, 27 decliners and 2 flats

  • It’s time for fundamentals and trial “stones” to be MORE considered VALUED; yet eanings usually bounce share pricing

Henry’omics: We need to more than consider the economic/political environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  • Consumer sentiment held at record-low levels in April even as a ceasefire took. The Un of Michigan’s Survey of Consumers showed the sentiment gauge at 49.8, slightly above the initial April reading of 47.6 and better than the Dow Jones consensus estimate for 48.6. However, the reading marked a 6.6% decline from a month ago and a 4.6% decrease from the same time a year ago, and is the lowest on record.
  • U.S. oil prices pulled back following the development. U.S. West Texas Intermediate futures settled above $94 per barrel after falling 1.51%. International benchmark Brent crude futures closed marginally higher at above $105 a barrel.

The CBOE Fear (VIX) index, Friday closed at 18.70, after Thursday’s 19.29, Wednesday’s 18.74, Tuesday’s 20.59, Monday’s 19.04 and last Friday’s 17.39

Metrics: Friday …

  • The RUT was up +11.90 points or +0.43%,
  • The XLV was down -2.06 points or -1.41%,
  • The NBI was down -65.73 points or -1.10%;
  • The XBI was down -1.21 points or -0.90%
  • The IWM was up +1.12 or +0.41%;
  • The IBB was down -1.75 points or -1.02%,
  • The VIX was down -0.61 points or -3.16% at to 18.70
  • The SPX was up +56.68 or +0.80% to 7,165.08

 

Q2/26 – 1 holiday, 1 neutral, 7 negative and 8 positive closes

  • Q1 -March – 9 positive and 13 negative closes
  • February – 1 holiday, 8 negative and 11 positive sessions
  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

 

Friday Closing UP (11 of 11)

  • AxoGen (AXGN +$1.84 after Thursday’s +$0.41 after Wednesday’s +$1.11 after Tuesday’s -$1.34 after Monday’s -$1.27),
  • IQVA Holdings (IQV +$1.60 after Thursday’s -$14.52 after Wednesday’s -$0.47 after Tuesday’s -$1.18 after Monday’s +$0.41),
  • Capricor Therapeutics (CAPR +$1.41 after Thursday’s -$1.14 after Wednesday’s -$0.34 after Tuesday’s +$1.13 after Monday’s -$0.49),
  • Vericel (VCEL +$1.24 after Thursday’s +$0.03 after Wednesday’s +$0.70 after Tuesday’s -$2.14 after Monday’s +$0.13),
  • uniQure NV (QURE +$0.49),
  • Lenz Therapeutics (LENZ +$0.23 after Thursday’s -$0.86),
  • Precigen (PGEN +$0.17 after Thursday’s $0.00),
  • Agenus (AGEN +$0.14),
  • MiMedx (MDXG +$0.08 after Thursday’s +$0.04)
  • Mesoblast (MESO +$0.01),
  • Fate Therapeutics (FATE +$0.01),

Flat (2)

  • Generation Bio (GBIO) – acquired
  • Harvard Apparatus RT (OTCQB: HRGN)

Friday’s Closing DOWN (10 of 30):

  • Alnylam Pharmaceuticals (ALNY -$8.25 after Thursday’s +$3.21 after Wednesday’s +$2.15 after Tuesday’s -$2.51 after Monday’s +$1.28),
  • CRISPR Therapeutics (CRSP -$6.40 after Thursday’s -$1.24 after Wednesday’s +$0.88 after Tuesday’s -$2.15 after Monday’s -$0.30),
  • Vertex (VRTX -$4.81 after Thursday’s -$2.57 after Wednesday’s +$1.08 after Tuesday’s -$2.59 after Monday’s -$2.02),
  • Beam Therapeutics (BEAM -$3.05 after Thursday’s -$1.53 after Wednesday’s +$1.00),
  • Intellia Therapeutics (NTLA -$2.24),
  • Moderna (MRNA -$2.12 after Thursday’s -$2.75 after Wednesday’s +$1.37),
  • Ionis Pharmaceuticals (IONS -$0.82),
  • Dyne Therapeutics (DYN -$0.64 after Thursday’s -$0.77),
  • Supernus Therapeutics (SUPN -$0.63 after Thursday’s +$0.10 after Wednesday’s +$1.17 after Tuesday’s -$2.13),
  • Arrowhead Pharmaceuticals (ARWR -$0.49 after Thursday’s +$0.48 after Wednesday’s +$2.87 after Tuesday’s +$1.80),

 

The Bottom Line: More of the … WHY and a lot of what ifs …

A Friday low as retail  investors bolted as “uncle algo and his electronic trading dwarfs” also took a bite!

The S&P 500 rose 0.8% and Nasdaq gained 1.6%. capping-off their 4th-straight week of gains with record closes while the Dow fell 85 points, or 0%.

For the week:

  • The S&P 500 is up 39.02 points, or 0.5%.
  • The Dow is down 216.72 points, or 0.4%.
  • The Nasdaq is up 368.12 points, or 1.5%.
  • The Russell 2000 is up 10.10 points, or 0.4%.

 

April 4th Week:

  • 4/24 – Friday closed negative with 11 incliners, 27 decliners and 2 flats
  • 4/23 - Thursday closed negative with 7 incliners, 30 decliners and 3 flats
  • 4/22 – Wednesday closed positive with 30 incliners, 9 decliners and 1 flat
  • 4/21 – Tuesday closed negative with 5 incliners, 33 decliners and 2 flats
  • 4/20 - Monday closed negative with 16 incliners, 21 decliners and 3 flats

 

Q1/26 Earnings Release Dates:

  • AxoGen (AXGN) – Tuesday, 4/28
  • Alnylam Pharmaceuticals (ALNY) -Thursday, 4/30
  • IQVIA Holdings (IQV) and Supernus Therapeutics (SUPN) – Tuesday, 5/5
  • Vericel (VCEL) – Thursday, 5/7

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there – closed end funds” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Friday: AxoGen (AXGN), IQVA Holdings (IQV) and Capricor Therapeutics (CAPR)
  • Thursday: Alnylam Pharmaceuticals (ALNY), AxoGen (AXGN) and Supernus Therapeutics (SUPN)
  • Wednesday: Alnylam Pharmaceuticals (ALNY), Arrowhead Pharmaceuticals (ARWR) and Moderna (MRNA)
  • Tuesday: BioNTech (BNTX), Arrowhead Pharmaceuticals (ARWR) and Capricor Therapeutics (CAPR)
  • Monday: BioNTech (BNTX), Moderna (MRNA) and BioLife Solutions BLFS)

The worst three (3) in the session: Losers’

  • Friday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Vertex (VRTX),
  • Thursday: IQVA Holdings (IQV), BioNTech (BNTX) and Vertex (VRTX)
  • Wednesday:  BioNTech (BNTX), IQVA Holdings (IQV) and Mesoblast (MESO)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and CRISPR Therapeutics (CRSP)
  • Monday: Vertex (VRTX), AxoGen (AXGN) and Ionis Pharmaceuticals (IONS)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.